H. Lee Moffitt Cancer Center and Research Institute: Neoplasms, Plasma Cell trials

The registry lists 27 Neoplasms, Plasma Cell studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 1 are open to participants now and 13 have results posted.

Early Phase 1 1Phase 1 9Phase 2 21No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed MyelomaRecruitingNCT06947083Phase 2
• Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple MyelomaCompletedNCT04151667Phase 2Results posted
• Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideTerminatedNCT03411031Phase 2Results posted
• Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple MyelomaCompletedNCT02780609Phase 1/2Results posted
• Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)CompletedNCT02722941Phase 2Results posted
• Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple MyelomaCompletedNCT02186834Phase 1/2Results posted
• Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous TransplantCompletedNCT01852591Not applicableResults posted
• Pomalidomide in Combination With High Dose Dexamethasone and Oral CyclophosphamideCompletedNCT01432600Phase 1/2Results posted
• Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple MyelomaCompletedNCT01054144Phase 2Results posted
• Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple MyelomaCompletedNCT00948922Phase 2Results posted
• Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)CompletedNCT00750815Phase 1/2Results posted
• Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)CompletedNCT00617591Phase 2Results posted
• Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.CompletedNCT00325416Phase 1/2Results posted
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2Results posted
• Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell ImmunotherapyCompletedNCT05763563Not applicable
• Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedNCT05065866Phase 1
• Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)CompletedNCT02851056Early Phase 1
• Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatWithdrawnNCT02802163Phase 1/2
• Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression FracturesWithdrawnNCT01175278Not applicable
• A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple MyelomaTerminatedNCT00361088Phase 1/2
• Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple MyelomaCompletedNCT00012350Phase 2
• Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow TransplantTerminatedNCT00005852Phase 2
• Bone Marrow Transplant in Treating Patients With Hematologic CancersCompletedNCT00005797Phase 2
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple MyelomaCompletedNCT00005792Phase 1
• Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow TransplantationTerminatedNCT00005641Phase 2
• CI-994 in Treating Patients With Advanced MyelomaCompletedNCT00005624Phase 2
• Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic DisordersCompletedNCT00005622Phase 2